Fifteen-Year Biochemical Relapse-Free Survival, Cause-Specific Survival, and Overall Survival Following I125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience

Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity

“…Seed placement is readily identified in the sagittal view. Although the intraoperative planning technique is gaining in popularity, high-quality implants also can be achieved in expert hands using the older preplanned technique with preloaded needles [7].…”

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

“…Management options for patients with low or intermediate risk prostate cancer and a life expectancy of less than 10 years include active surveillance (1), radical prostatectomy (2), external beam radiation therapy (EBRT), low-dose rate (LDR) brachytherapy monotherapy (3,4), or high-dose--rate (HDR) brachytherapy (5,6). Since cure rates are similar among these treatment options (7), health-related quality of life (HRQOL) is an important factor in a patient's decision-making process (8).…”

Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer

“…The biochemical relapse-free survival (bRFS) rate at 5 years has been reported to range from 82 to 96 % [2]. It is therefore a curative alternative to radical prostatectomy, with comparable long-term survival and biochemical control, and low toxicity [3][4][5][6][7][8][9][10]. In addition to the logistics with respect to the implantation procedure, the importance of dosimetric parameters, the implementation of radiation safety procedures, and pre-and post-PSI documentation are essential in determining the quality of care.…”